Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

19%

3 trials in Phase 3/4

Results Transparency

10%

1 of 10 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment reporting

Analytics

Phase 2
10(66.7%)
N/A
2(13.3%)
Phase 3
2(13.3%)
Phase 4
1(6.7%)
15Total
Phase 2(10)
N/A(2)
Phase 3(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT07500233Phase 2Not Yet Recruiting

Trial of Oral Community SVMP INhibitors for Snakebite

Role: collaborator

NCT04332068Phase 2Completed

Ivermectin Safety in Small Children

Role: collaborator

NCT06404333Phase 2Completed

Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15)

Role: collaborator

NCT06148792Phase 3Recruiting

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria

Role: collaborator

NCT03529396Phase 2Completed

Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Role: lead

NCT05044637Phase 2Completed

Study to Evaluate Primaquine for Radical Cure of Uncomplicated Plasmodium Vivax Malaria in Children

Role: lead

NCT05096702Unknown

Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil

Role: lead

NCT03208907Phase 3Completed

DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil

Role: lead

NCT05289206Not ApplicableUnknown

Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity

Role: lead

NCT04033640Not ApplicableCompleted

Evaluation of a Diagnostic to Identify Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency in Brazil

Role: collaborator

NCT04323527Phase 2Completed

Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2

Role: lead

NCT04342650Phase 2Completed

Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection

Role: lead

NCT04343729Phase 2Completed

Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19

Role: lead

NCT04789356Phase 4Unknown

Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity

Role: lead

NCT02919605Phase 2Completed

Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis

Role: lead

NCT03281226Phase 2Unknown

RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection

Role: lead

All 16 trials loaded